A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Senaparib (Primary)
Indications Advanced breast cancer; Carcinoma; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors IMPACT Therapeutics

31 Jan 2023 Results of safety and preliminary efficacy of senaparib in patients with advanced solid tumors, published in the Cancer
21 Sep 2020 Results assessing updated safety and preliminary antitumor activity presented at the 45th European Society for Medical Oncology Congress
20 Aug 2020 According to a Shanghai Junshi Biosciences media release, the updated results from the study will be presented at upcoming world-class clinical conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com